Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT05481476 Recruiting - Clinical trials for Pancreatic Neoplasms

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Start date: September 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with sintilimab and AG in first-line therapy of patients with locally advanced or metastatic pancreatic cancer.

NCT ID: NCT05481463 Recruiting - Clinical trials for Pancreatic Neoplasms

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Start date: March 28, 2022
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

NCT ID: NCT05462496 Recruiting - Pancreatic Cancer Clinical Trials

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Start date: March 13, 2023
Phase: Phase 2
Study type: Interventional

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

NCT ID: NCT05442749 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer

PARPi-PANC
Start date: October 28, 2022
Phase: Phase 2
Study type: Interventional

This trial is a single arm open-label, phase II aiming to assess the clinical activity of niraparib in chemotherapy-naïve biomarker-selected pancreatic cancer patients.

NCT ID: NCT05438797 Recruiting - Clinical trials for Advanced Pancreatic Cancer

The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Start date: April 2, 2021
Phase: Early Phase 1
Study type: Interventional

Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.

NCT ID: NCT05438667 Recruiting - Pancreatic Cancer Clinical Trials

TCR-T Cell Therapy on Advanced Pancreatic Cancer

Start date: June 7, 2022
Phase: Early Phase 1
Study type: Interventional

The primary aim of this study is to evaluate the efficacy of KRAS mutant antigen specific TCR-T cells in the treatment of patients with advanced pancreatic cancer. The secondary aim is to evaluate the pharmacokinetic/pharmacodynamic characteristics of TCR-T cell therapy in patients with advanced pancreatic cancer and the survival of TCR-T cells. The investigators will evaluate the changes of tumor microenvironment after treatment of advanced pancreatic cancer with KRAS mutant antigen specific TCR-T cells; Evaluating the correlation between cytokines and the occurrence of CRS and neurotoxicity

NCT ID: NCT05438459 Recruiting - Pancreatic Cancer Clinical Trials

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

Start date: June 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I Part : Confirm the safety of GAIA-102 GAIA-102 as a single agent or GAIA-102 and pembrolizumab in combination for Advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part : Research the efficacy and safety of as a single agent or GAIA-102 and pembrolizumab for Advanced gastrointestinal cancer of microsatellite stable with malignant ascites at the recommended dose of GAIA-102 decided in the Phase I part.

NCT ID: NCT05430841 Recruiting - Pancreatic Cancer Clinical Trials

Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compared with 18F-FDG PET/CT.

NCT ID: NCT05429203 Recruiting - Clinical trials for Pancreatic Neoplasms

Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope

Start date: October 25, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to compare the success rates of procedure success and complication rates in patients undergoing Endoscopic retrograde cholangiopancreatography (ERCP) using two types of currently available endoscopes. These are (1) duodenoscope with a Single-use distal cover or (2) a conventional reusable duodenoscope.

NCT ID: NCT05428358 Recruiting - Pancreatic Cancer Clinical Trials

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

MAGIPAC
Start date: August 30, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.